
Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Niel... more
| Publishes | Weekly | Episodes | 56 | Founded | 3 years ago |
|---|---|---|---|---|---|
| Number of Listeners | Categories | Life SciencesScience | |||

Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences investments in Europe via the Life Sciences VC Coalition. We chat about bu... more
Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines.
We discuss how Immunethep could challenge Pfizer’s $7bn+ Prevnar, and how one ... more
We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned.
We cover Bial’s pipeline, including treatments for epilepsy and Parkinson’s, and why Bial’s multig... more
Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to s... more
People also subscribe to these shows.




I’m one of the founders so I’m a bit biased. But if it try to listen to it as a user, I find it to be one of the best video podcasts, especially with Europeans speakers and mostly for a European audience. Would love to hear what you think
Key themes from listener reviews, highlighting what works and what could be improved about the show.
How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.
Apple Podcasts | #228 | |
Apple Podcasts | #152 | |
Apple Podcasts | #217 | |
Apple Podcasts | #244 | |
Apple Podcasts | #248 | |
Apple Podcasts | #49 |
Recent interactions between the hosts and their guests.
Listeners, social reach, demographics and more for this podcast.
| Listeners per Episode | |
|---|---|
| Gender Skew | |
| Location | |
| Interests | |
| Professions | |
| Age Range | |
| Household Income | |
| Social Media Reach |
Across recent episodes, conversations skew biotech-forward: executives, researchers, and investors discuss breakthroughs in biotech, pharma, vaccines, and cell therapies, along with funding, regulation, and market strategy. Expect candid takes on industry challenges, European biotech dynamics, and the evolving business models driving biotech innovation, from AI-powered drug development to novel vaccine platforms and rare-disease therapies. Noteworthy traits include a strong European focus, a penchant for contrarian or forward-looking viewpoints, and an emphasis on practical path-to-market insights for startups and scaleups.
Rephonic provides a wide range of podcast stats for Flot.bio x Philip Hemme. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Flot.bio x Philip Hemme and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.
Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Flot.bio x Philip Hemme, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.
Rephonic provides comprehensive predictive audience data for Flot.bio x Philip Hemme, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.
To see how many followers or subscribers Flot.bio x Philip Hemme has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.
These podcasts share a similar audience with Flot.bio x Philip Hemme:
1. Biotech Hangout
2. BioCentury This Week
3. The Readout Loud
4. The BioCentury Show
5. Beyond Biotech - the podcast from Labiotech
Flot.bio x Philip Hemme launched 3 years ago and published 56 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.
Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.
Rephonic pulls ratings and reviews for Flot.bio x Philip Hemme from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.
View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.
Rephonic provides full transcripts for episodes of Flot.bio x Philip Hemme. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.
Recent guests on Flot.bio x Philip Hemme include:
1. Sander van Deventer
2. Pedro (Immunethep)
3. Bruno (Immunethep)
4. António Portela
5. Claus Crone Fuglsang
6. Fredrik Tiberg
7. Alessandro Riva
8. Pascal Touchon
To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.